Journal of Nuclear Cardiology

, Volume 25, Issue 2, pp 526–531 | Cite as

Assessment of dyssynchrony by gated myocardial perfusion imaging does not improve patient management

  • Ran Lee
  • Ravi V. Shah
  • Venkatesh L. Murthy
Debate Article


Clinical trials have demonstrated improved outcomes with cardiac resynchronization therapy in patients with heart failure and electrical evidence of dyssynchrony. There has been intense effort at developing imaging markers of dyssynchrony with the aim of improved risk stratification. However, these efforts have not been fruitful to date. This article discusses mechanisms of cardiac dyssynchrony, reviews clinical data supporting resynchronization therapy, and addresses the lack of convincing evidence to support the use of noninvasive imaging measures of dyssynchrony in improving patient management.


Cardiomyopathy Heart failure Dyssynchrony Cardiac resynchronization therapy Dyssynchrony imaging 



Dr. Lee has no relevant disclosures. Dr. Murthy owns stock in General Electric, Cardinal Health and Covidien. He has received speaker’s fees from Bracco Diagnostics and Ionetix. He has received research funding from INVIA Medical Imaging Solutions. Drs. Shah and Murthy are supported by Grant 1R01HL136685 from the National Heart, Lung, and Blood Institute.

Supplementary material

12350_2017_1022_MOESM1_ESM.pptx (316 kb)
Supplementary material 1 (PPTX 315 kb)


  1. 1.
    Fang J, Mensah G, Croft JB, Keenan NL. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol. 1979;2008(52):428–34.Google Scholar
  2. 2.
    Go AS, Mozaffarian D, Roger VL, et al. Executive summary: Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation. 2013;127:143–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–88.CrossRefPubMedGoogle Scholar
  4. 4.
    Rosen B, Lardo A, Berger D. Imaging of myocardial dyssynchrony in congestive heart failure. Heart Fail Rev. 2006;11:289–303.CrossRefPubMedGoogle Scholar
  5. 5.
    Shamim W, Francis DP, Yousufuddin M, et al. Intraventricular conduction delay: A prognostic marker in chronic heart failure. Int J Cardiol. 1999;70(2):171.CrossRefPubMedGoogle Scholar
  6. 6.
    Baldasseroni S, Opasich C, Gorini M, et al. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: A report from the Italian network on congestive heart failure. Am Heart J. 2002;143(3):398.CrossRefPubMedGoogle Scholar
  7. 7.
    Duncan AM, Francis DP, Gibson DG, Henein MY. Limitation of exercise tolerance in chronic heart failure: Distinct effects of left bundle-branch block and coronary artery disease. J Am Coll Cardiol. 2004;43(9):1524.CrossRefPubMedGoogle Scholar
  8. 8.
    Abraham WT, Fisher WG, Smith AT, on behalf of the MIRACLE Study Group, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Cleland JG, Daubert JC, Erdmann E, on behalf of the Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMedGoogle Scholar
  10. 10.
    Serri K, Lafitte S, Amyot R, Sauve C, Roudaut R. Echocardiographic evaluation of cardiac dyssynchrony. Can J Cardiol. 2007;23(4):303–10.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Cheng A, Helm RH, Abraham TP. Pathophysiological mechanisms underlying ventricular dyssynchrony. Europace. 2009;11:v10–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Park RC, Little WC, O’Rourke RA. Effect of alteration of left ventricular activation sequence on the left ventricular end-systolic pressure–volume relation in closed-chest dogs. Circ Res. 1985;57:706–17.CrossRefPubMedGoogle Scholar
  13. 13.
    Onishi T, Onishi T, Marek J, et al. Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome. Circ Heart Fail. 2013;6:685–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Verhaert D, Popović ZB, De S, et al. Impact of mitral regurgitation on reverse remodeling and outcome in patients undergoing cardiac resynchronization therapy. Circ Cardiovasc Imaging. 2012;5:21–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Trichon BH, Felker GM, Shaw LK, et al. Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol. 2003;91:538–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003;107:28–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Sundell J, Engblom E, Koistinen J, et al. The effects of cardiac resynchronization therapy on left ventricular function, myocardial energetics and metabolic reserve in patients with dilated cardiomyopathy and heart failure. J Am Coll Cardiol. 2004;43:1027–33.CrossRefPubMedGoogle Scholar
  18. 18.
    Braunschweig F, Sorensen J, von Bibra H, et al. Effects of biventricular pacing on myocardial blood flow and oxygen consumption using carbon-11 acetate positron emission tomography in patients with heart failure. Am J Cardiol. 2003;92:95–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Gorcsan J 3rd, Abraham T, Agler DA, et al. Echocardiography for cardiac resynchronization therapy: Recommendations for performance and reporting—a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr. 2008;21:191–213.CrossRefPubMedGoogle Scholar
  20. 20.
    Henneman MM, Chen J, Ypenburg C, et al. Phase analysis of gated myocardial perfusion single-photon emission computed tomography compared with tissue doppler imaging for the assessment of left ventricular dyssynchrony. J Am Coll Cardiol. 2007;40:1708–14.CrossRefGoogle Scholar
  21. 21.
    Daya HA, Malhotra S, Soman P. Radionuclide assessment of left ventricular dyssynchrony. Cardiol Clin. 2016;34:101–18.CrossRefPubMedGoogle Scholar
  22. 22.
    Daubert C, Gold MR, on behalf of the REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE trial. J Am Coll Cardiol. 2009;54:1837–46.CrossRefPubMedGoogle Scholar
  23. 23.
    Moss AJ, Hall WJ, on behalf of the MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1328038.CrossRefGoogle Scholar
  24. 24.
    Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.CrossRefPubMedGoogle Scholar
  25. 25.
    Yu CM, Abraham WT, Bax J, et al. Predictors of response to cardiac resynchronization therapy (PROSPECT)—study design. Am Heart J. 2005;149:600–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Ruschitzka F, Abraham WT, Sing JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefPubMedGoogle Scholar
  27. 27.
    Gorscan J 3rd, Oyenuga O, Habib PJ, et al. Relationship of echocardiographic dyssynchrony to long-term survival after cardiac resynchronization therapy. Circulation. 2010;122(19):1910.CrossRefGoogle Scholar
  28. 28.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51:e1–62.CrossRefPubMedGoogle Scholar
  29. 29.
    Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation. 2012;126:1784–800.CrossRefPubMedGoogle Scholar
  30. 30.
    Henneman MM, Chen J, Dibbets-Schneider P, et al. Can LV dyssynchrony as assessed with phase analysis on gated myocardial perfusion SPECT predict response to CRT? J Nucl Med. 2007;48:1104–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Goldberg AS, Alraies MC, Cerquiera MD, et al. Prognostic value of left ventricular mechanical dyssynchrony by phase analysis in patients with non-ischemic cardiomyopathy with ejection fraction 35-50% and QRS < 150 ms. J Nucl Cardiol. 2014;21(1):57–66.CrossRefPubMedGoogle Scholar
  32. 32.
    Badhwar N, James J, Hoffmayer KS, et al. Utility of equilibrium radionuclide angiogram-derived measures of dyssynchrony to predict outcomes in heart failure patients undergoing cardiac resynchronization therapy. J Nucl Med. 2016;57:1880–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Mori H, Isobe S, Suzuki S, et al. Prognostic value of left ventricular dyssynchrony evaluated by gated myocardial perfusion imaging in patients with chronic kidney disease and normal perfusion defect scores. J Nucl Cardiol. 2017. doi: 10.1007/s12350-017-0889-9.Google Scholar
  34. 34.
    Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay, on behalf of the MUSTIC Study Investigators. New Engl J Med. 2001;344(12):873–80.CrossRefPubMedGoogle Scholar
  35. 35.
    Young JB, Abraham WT, Smith AL, et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA. 2003;289(20):2685–94.CrossRefPubMedGoogle Scholar
  36. 36.
    Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure, on behalf of the RAFT Trial Investigators. N Engl J Med. 2010;363(25):2385–95.CrossRefPubMedGoogle Scholar

Copyright information

© American Society of Nuclear Cardiology 2017

Authors and Affiliations

  1. 1.Frankel Cardiovascular Center, Michigan MedicineUniversity of MichiganAnn ArborUSA
  2. 2.Massachusetts General HospitalBostonUSA

Personalised recommendations